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Membrane preparations of cells expressing the cloned rat hypothalamus melanocortin receptor, MC3, have been photoaffinity labelled using a 
radiolabelled photoreactive analogue of a-MSH, [‘251-Tyr2,Nle4,0-Phe7,ATB-Lys”]a-MSH. SDS-PAGE followed by autoradiography showed asingle 
band at 53-56 kDa for the native receptor or 35 kDa after deglycosylated with PNGase F, consistent with the predicted cDNA sequence. Receptor 
binding studies with a-MSH, y-MSH and [Nle4,0-Phe’Ja-MSH established that a-MSH and y-MSH had similar affinities while [Nle4,D-Phe7]a-MSH 
bound 100 times more strongly. These results uggest that the receptor recognises the conserved ‘core sequence’ (-Met-Glu/Gly-His-Phe-Arg-Trp-) 
of MSH/ACTH peptides. The binding affinities of alanine-substituted analogues of a-MSH were determined to investigate he role of individual 
residues in ligand-receptor interactions. While in the terminal regions only the replacement of Tyr’ reduced the affinity of the peptide, replacement 
of Met4, Phe’, Arg* and Trp’ within the peptide core led to a significant loss of affinity. Glu’ appeared unimportant for receptor recognition. 
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1. Introduction 
Recently, several receptors for melanocortin peptides 
have been discovered in the brain [l-6] where MSH pep- 
tides have a multitude of functions [7-l 11. Screening of 
cDNA libraries revealed the existence of structurally re- 
lated receptors in the human limbic system [3] and rat 
hypothalamus [6]. These receptors have subsequently 
been named MC3 [3,12]. Studies with endogenous MSH 
and ACTH ligands have led to the proposal that this 
receptor might provide a possible site of action for a 
specific physiological role for y-MSH [6], but the use of 
synthetic ligands has been limited. In contrast, structure- 
activity relationships for the MC1 receptor found in 
melanocytes and melanoma cells have been widely inves- 
tigated [ 131. 
In this study we have analysed the molecular weight 
and extent of glycosylation of the cloned MC3 receptor 
from rat hypothalamus expressed in 293 cells. A potent 
derivative of ol-MSH, [“‘I-Tyr2,Nle4,0-Phe7,ATB- 
Lys”]a-MSH, which had previously been used to suc- 
cessfully characterise the cc-MSH (MCl) receptor from 
B16 murine melanoma cells [14] and rat Schwann cells 
[15], has been employed in these photoaffinity labelling 
experiments. Binding of a-MSH, I/-MSH and [Nle4,D- 
Phe7]a-MSH to the receptor was studied and alanine- 
substituted analogues of ol-MSH were also tested in this 
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assay to investigate the influence of individual amino 
acids on receptor recognition. Although the binding of 
various MSH peptides to this receptor has been studied 
previously [6], this is the first attempt to systematically 
study the relationship between ligand structure and MC3 
receptor affinity by using an alanine scan. We have previ- 
ously used this method to investigate the structure-activ- 
ity relationships for the MC1 receptor from murine mel- 
anoma cells [16]. 
2. Materials and methods 
2.1. Peptide synthesis and radioiodination 
a-MSH [17], [Nle4,D-Phe’]a-MSH, [Nle4,t+Phe7,ATB-Lys”]a-MSH 
[ 141 and alanine analogues ofa-MSH [ 161 were synthesised and purified 
as previously described. I/,-MSH was obtained commercially (Sigma). 
[Nle4,0-Phe’]a-MSH and [Nle4,0-Phe7,ATB-Lys”]a-MSH were iodi- 
nated at Ty? using the method of Eberle [l3]. The mono-iodinated 
product was used in all experiments. 
2.2. Cell culture 
Transformed human 293 cells expressing the rat MC3 receptor were 
generously provided by R.D. Cone [6] and were cultured in RPM1 1640 
medium (G&co) containing 10% heat-inactivated foetal calf serum 
(ICN), 2 mM L-glutamine, 1% non-essential amino acids, 50 IUlml 
penicillin, 50 &ml streptomycin and 250 pg/ml amphotericin B in an 
humidified atmosphere of 95% sir/5% CO,. 
2.3. Binding of [“‘I-Ty?, Nle4,0-Phe’]a-MSH and competitive binding 
assay 
The binding assay was based on a previously described method [17] 
adapted from Siegrist et al. [l8]. Cells were distributed into 96-well 
filtration plates (Millipore) at a density of 10’ cells per well and incu- 
bated for 4 h at 37°C. Cells were then washed with serum-free RPM1 
1640 by filtration using a vacuum manifold (Millipore). They were then 
incubated with 0. I ml binding medium for 24 h at 0-4”C. The binding 
buffer consisted of serum-free RPM1 1640 medium containing 25 mM 
0014-5793/94/$7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(94)00725-X 
30 U.G. Sahm et al. IFEBS Letters 350 (I 994) 29-32 
N-(2-hydroxyethyl)piperazine-K-2-ethane sulphonic acid (HEPES)/ 
NaOH (pH 7.4) 0.2% bovine serum albumin (BSA) and various con- 
centrations of [“51-Tyr’,Nle4,0-Phe’]a-MSH. Non-specific binding was 
determined in the presence of a IOOO-fold excess unlabelled [Nle4,0- 
Phe’la-MSH. Four replicates were assayed for each concentration 
point. After the incubation, cells were washed twice with serum-free 
RPM1 1640 and the filters punched out using the Multiscreen Assay 
System (Millipore). The filters were then counted on a LKB Wallac 
1277 gammamaster. 
Competitive binding experiments were carried out as above but in the 
presence of I x lo-“’ M [‘251-Tyr’,Nle4,0-Phe7]a-MSH and varying con- 
centrations of the unlabelled analogues. Significant differences were 
determined from one-way analysis of variance using Fisher’s multiple 
comparison procedure at the 99% confidence interval unless otherwise 
stated. The coefficient of variance associated with replicate wells was 
less than 10%. 
2.4. Photoajjinity hhelling and SDSlpolyacrylamide gel electrophoresis 
Membrane preparations of transformed 293 cells were photoaffinity 
labelled with [‘Z51-TyrZ,Nle4,0-Phe7,ATB-Lys”]a-MSH and subsequent 
SDS-PAGE of the solubilised labelled proteins was carried out as pre- 
viously described [14]. 
2.5. Enzymatic deglycosylation 
[‘~51-Tyr2,Nle4,n-Phe7,ATB-Lys”]a-MSH labelled membrane prepa- 
rations were suspended in 50 mM phosphate buffer pH 7 containing 
20 mM EDTA, 1% octylglucoside, 0.1% SDS, 1% 2-mercaptoethanol 
and protease inhibitors (antipain, aprotinin, leupeptin and pepstatin at 
1 mg.ml-’ each). PNGase F was added to a fmal concentration of IO 
units’mg-‘. The samples were incubated at 37°C for 3 h, solubilised in 
electrophoresis sample buffer and subjected to SDS-PAGE. 
3. Results and discussion 
The dissociation constant (Kd) for the interaction of 
[‘2S1-Tyr2,Nle4,n-Phe7]cl_MSH with the MC3 receptor 
was obtained from three replicate binding isotherms and 
was estimated by lMINsQ non-linear least-squares re- 
gression analysis to be 1.66 nM. Scatchard analysis of 
the binding isotherm showed only one population of 
receptors. The number of receptors per cell was relatively 
high, varying between 35,000 and 50,000. 
Photoaffinity labelling of the MC3 receptor using [‘*‘I- 
Tyr2,Nle4,0-Phe7,ATB-Lys”]a-MSH followed by SDS- 
PAGE and autoradiography showed a protein band at 
53-56 kDa (Fig. 1, lanes 2 and 4). In the presence of a 
lOOO-fold excess unlabelled [Nle4,D-Phe7]a-MSH this 
band was completely suppressed (Fig. 1, lanes 3 and 5), 
suggesting that it represented the specifically labelled 
melanocortin receptor. Treatment with hot buffer solu- 
tion, which was routinely performed with SDS-PAGE 
samples, resulted in the radioactivity remaining at the 
origin of the gel, indicating aggregation of the protein 
(Fig. 1, lane 6). This phenomenon has also been observed 
with the a-MSH receptor from B16 murine melanoma 
cells [14]. The intense band at the front of lanes 2,4 and 
6 represents specifically bound ligand not removed by 
the washing procedure employed before solubilisation 
which dissociates from the receptor on introduction to 
the SDS buffer. In lanes 3, 5 and 7 the band at the front 
represents the small amount of free ligand remaining 
after washing. 
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Fig. I. Autoradiography of gel of solubilized membrane proteins la- 
belled with [‘Z51-Tyr*,Nle4,0-Phe’,ATB-Lys”]a-MSH. Lane 1, “C-la- 
belled molecular mass standards; lanes 2 and 4, labelled membrane 
proteins, lanes 3 and 5, membrane proteins in the presence of radioli- 
gand and excess non-labelled [Nle4,0-Phe’]a-MSH; lane 6, labelled 
membrane proteins after SDS solubilisation in hot buffer solution; lane 
7, same treatment as in lane 6 in the presence of excess non-labelled 
[Nle4,0-Phe7]a-MSH. 
PNGase F treatment of the photoaffinity labelled 
membranes demonstrated the presence of N-linked car- 
bohydrate side-chains on the receptor protein. PNGase 
F is known to cleave asparagine-bound N-glycans to give 
proteins free of N-linked carbohydrate chains [19,20]. 
After 3 h of treatment, the labelled receptor complex was 
reduced to an apparent molecular weight of approxi- 
mately 35 kDa (Fig. 2, lane 6). This molecular weight is 
in agreement with the amino acid sequence of the recep- 
tor [6] and suggests that the MC3 receptor, like the MC1 
1 2 3 4 5 6 7 
Fig. 2. Autoradiography of gel of solubilized membrane proteins la- 
belled with [‘*SI-TyrZ,Nle4,0-Phe7,ATB-Lys”]a-MSH. Lane I, 14C-la- 
belled molecular mass standards; lane 2. labelled membrane proteins; 
lane 3, membrane proteins in the presence of radioligdnd and excess 
non-labelled [Nle“,n-Phe’]a-MSH; lanes 4 and 5, as lanes 2 and 3 with 
lower loading; lane 6, labelled membrane proteins after treatment with 
PNGase F; lane 7, labelled and PNGase F treated membrane proteins 
in the presence of excess non-labelled [Nle4,0-Phe’]a-MSH. 
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Table 1 
Dissociat ion constants ( + S.D.) and relative binding affinities of MSH 
peptides 
Binding (Kd) Relat ive 
b inding 
[NIe4,D-Phe7]ct-MSH 2.15 x 10 -8 + 1.73 × 10 -8 96.28 
(n = 14) 
~-MSH 2.07 × 10 6 + 1.18 × 10 -6 l 
(n = 4) 
7 -MSH 3.24 × 10 6 + 2.15 × 10 -6 0.64 
(n = 4) 
receptor [21], does not contain additional O-linked car- 
bohydrates. Two other bands appear at 70 and 28 kDa 
and are believed to represent a dimer of the receptor and 
a degradation product respectively. All three bands 
could be inhibited in the presence of excess unlabelled 
ligand (Fig. 2, lane 7). Incubations with PNGase F for 
longer periods of time did not result in any further 
change in the apparent molecular weight, therefore it was 
assumed that the deglycosylation was complete. Broad- 
ening of the specifically labelled bands in lanes 2, 4 and 
6 of Fig. 2 and the routinely observed specific 125I activity 
at higher apparent molecular weights was attributed to 
poor solubilisation and aggregation of the receptor pro- 
teins. 
The dissociation constants for ~-MSH, ~'I-MSH, 
[Nlea,D-PheT]~-MSH and alanine-substituted analogues 
of ~-MSH were obtained from three or more replicate 
experiments using MINSQ non-linear least square re- 
gression (Tables 1 and 2). All peptides tudied were able 
to fully inhibit binding of [~25I-Tyr2,Nie4,D-PheT]~-MSH 
to the receptor at sufficiently high concentrations. In this 
study, ~-MSH and 7~-MSH showed a similar affinity as 
shown previously by Roselli-Rehfuss et al. [6], whereas 
[Nle4,D-Phe7]~-MSH bound 100 times more strongly 
Table 2 
Dissociat ion constants ( +_ S.D.) of  alanine analogues of ct-MSH and 
binding relative to ct-MSH 
Binding (K0) Relative 
binding 
ct-MSH 2.07 X 10 -6 --+ 1.18 X 10 6 (n = 4) 1 
[AIa']ct-MSH 3.08 × 10 -6 + 2.28 x 10 -6 (n = 3) 0.67 
[AlaZ]ct-MSH 1.50 × 10 -5 _+ 1.42 × 10 -5 (n = 3) 0.14 
[AIa3]ct-MSH 3.41 × 10 -6 _+ 4.18 × 10 -6 (n = 3) 0.61 
[Ala4]~-MSH 2.95 × 10 -5 + 2.20 × 10 -5 (n = 5) 0.070 
[AlaS]~-MSH 2.39 x 10 -6 ± 2.63 × 10 6 (n = 4) 0.87 
[Ala6]cz-MSH 1.25 × 10 5 + 1.13 × 10 -s (n = 3) 0.17 
[AIaT]cz-MSH 1.94 × 10 _4 +_ 7.36 × 10 -5 (n = 3) 0,011 
[AIaS]ct-MSH 4.21 × 10 -4 + 2.62 × 10 4 (n = 3) 0.0049 
[Alag]ct-MSH 1.72 × 10 -4 +_ 8.42 × 10 -5 (n = 3) 0,012 
[Alat°]ct-MSH 2.72 × 10 6 + 9.80 × 10 7 (n = 4) 0,76 
[AIaH]~z-MSH 7.49 × 10 -6 + 4.27 × 10 -6 (iT = 3) 0.28 
[Alat2]~-MSH 7.25 × 10 -7 ___ 1.74 × 10 -7 (n = 3) 2.86 
[Alaf3]ct-MSH 1.57 × 10 -6 __. 1.08 × 10 -6 (n = 3) 1,32 
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Fig. 3, Competi t ive binding isotherms of [Nle4,D-PheT]o~-MSH, ct-MSH 
and z1-MSH. 
(Fig. 3). This is in disagreement with the earlier findings 
[6], which showed only a 5-fold difference in binding 
between 0~-MSH and [Nle4,D-Phe7]~-MSH. These dis- 
crepancies may be explained by the experimental condi- 
tions used: equilibrium studies at 4°C were used in the 
work reported here whereas Roselli-Rehfuss et al. em- 
ployed l0 rain incubations at37°C [6]. The human equiv- 
alent of the MC3 receptor was also reported to respond 
similarly to a range of MSH peptides including 0~-MSH 
and [NIe4,D-PheV]0~-MSH [3] in the cAMP assay, al- 
though no binding data was reported. 
The Ko values of the alanine substituted analogues 
were higher than that of ~-MSH with two exceptions, the 
Ala 12 and Ala ~3 compounds. The latter two analogues 
had affinities of 2.9 and 1.3 relative to 0~-MSH which 
were not statistically different to a-MSH. The relatively 
low affinity of all the peptides except [Nle4,D-PheT]~- 
MSH was surprising but consistent, suggesting that an- 
other endogenous ligand for the MC3 receptor may exist. 
Except for the Tyr 2, alanine replacements can be made 
in the terminal regions of the 0~-MSH molecule (amino 
acids 1-3 and 10-13) without significant loss of affinity. 
[Ala2]a-MSH showed only 14% of the affinity of ~-MSH. 
Within the 'core sequence', substitution of Glu 5 can be 
made without altering the binding properties of the pep- 
tide, but replacement of all other residues leads to a 
significant loss of affinity. [AIa4]~-MSH and [Ala6]a- 
MSH retained 7% and 17% of the affinity of ~-MSH, 
respectively. The most important residues for receptor 
binding occurred in the -Phe7-ArgS-Trpg-triplet, with 
[AIaS]ct-MSH, [AIaS]~-MSH and [Alaq]0~-MSH having 
affinities of 0.01 l, 0.0049 and 0.012 times that of 0~-MSH 
(Fig. 4). Similar results have also been obtained for a 
mouse MC1 receptor [16]. 
The results presented in this study are generally in 
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Fig. 4. Relative binding affinities of alanine-substituted analogues of 
a-MSH to the MCI and MC3 receptor. Values are relative to the 
affinity of a-MSH on the respective receptor. 
agreement with the view that this receptor might recog- 
mse the a-MSH,,_,,, ‘core sequence’ [3], although we 
have shown that the residue in position 10 is not crucial 
for the affinity. There is evidence that a tyrosine residue 
in position 2 is favourable for receptor binding. As yet, 
there is no evidence that y-MSH is the endogenous li- 
gand for the MC3 receptor but it is significant that 
LX-MSH and y-MSH had similar affinities, a situation 
which is not the case for the MCI receptor found on 
melanoma cells [22]. 
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